Compartion of effectiveness of valerian and melissa officinalis syrup and Alprazolam tablet on sleep quality and QOL in chronic heart failure patient s in Hajar heart clinic of Shahrekord.

Compartion of effectiveness of valerian and melissa officinalis syrup and Alprazolam tablet on sleep quality and QOL in chronic heart failure patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201204042289N2

Enrollment

160

Registered

2012-04-05

Start date

2010-03-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure disaeses. Ischaemic heart diseases

Interventions

Intervention 1: 40 patient in valerian group recived routine heart treatment with 12cc Valeriane officinalis syrup, an hour before going to bed every night within a month. Intervention 2: 40 patient i

Treatment - Drugs

40 patient in valerian group recived routine heart treatment with 12cc Valeriane officinalis syrup, an hour before going to bed every night within a month.

40 patient in secound group recived routine heart treatment with 12cc Melissa officinalis syrup, an hour before going to bed every night within a month.

40 patient in third group recived routine heart treatment with 12cc Melissa officinalis and valerian syrup(valeric), an hour before going to bed every night within a month.

40 patient in control group recived the routine heart treatment with Alprazolam tablet (from same institue) one hour before sleep for one month.

Eligibility

Sex/Gender

All

Age

40 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1-Suffering from CHF confirmed by patient's physician 2- The patients older than 40 years old 3- At least 6 score in the sleep quality questionnaire (PSQI) The exclusion criteria : 1-Unwillingness to continue participating in the study 2-Exhibiting sensitivity or physical problems pertinent to medicines during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Quality of life. Timepoint: One month. Method of measurement: Macknew questionaries.	—

Secondary

Measure	Time frame
Sleep quality. Timepoint: One month. Method of measurement: Petersburg Sleep Quality Investigation (PSQI) questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAliakbari Fateme

Shahrekord University of Medical Sciences

aliakbari@nm.mui.ac.ir; aliakbari@skums.ac.ir+98 38 1334 4912

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026